Berenberg Bank Reiterates Hikma Pharmaceuticals (HKMPF) Buy Recommendation

Berenberg Bank reiterated a Buy recommendation for Hikma Pharmaceuticals (OTCPK:HKMPF), setting an average one-year price target of $33.13, which suggests a 31.21% upside from its recent closing price of $25.25. This positive analyst outlook comes despite projected annual revenue decreasing by 10.45% to $2,880MM and non-GAAP EPS at $2.12. Institutional sentiment indicates a significant increase in total shares owned, up 38.93% to 8.508M, and a 24.30% rise in average portfolio weight dedicated to HKMPF, notably driven by John Hancock Disciplined Value International Fund increasing its stake by over 62%.

Analysis

Berenberg Bank reiterated a "Buy" recommendation for Hikma Pharmaceuticals (OTCPK:HKMPF) on November 6, 2025, setting an average one-year price target of $33.13/share. This target implies a significant 31.21% upside from the recent closing price of $25.25/share, despite projected annual revenue decreasing by 10.45% to $2,880MM and a non-GAAP EPS forecast of $2.12.

Institutional investor sentiment shows a robust increase in total shares owned, up 38.93% over the last three months to 8.508 million shares. The average portfolio weight dedicated to HKMPF across reporting funds also rose by 24.30% to 0.22%, indicating increased conviction. While the number of reporting funds decreased by 2.44%, the substantial increase in aggregate holdings suggests larger allocations by committed investors.

John Hancock Disciplined Value International Fund (JDIBX) notably increased its stake by 62.34% to 2,430K shares, boosting its portfolio allocation in HKMPF by 83.23%. This contrasts with several Vanguard funds (VGTSX, VTMGX, VEU) that reduced their shareholdings and portfolio allocations, highlighting divergent institutional strategies. The overall moderately positive sentiment and optimistic tone reflect the market's focus on the strong price target and net institutional accumulation.

Key Decisions for Investors

• Investors should consider the significant 31.21% upside implied by Berenberg Bank's reiterated "Buy" rating and $33.13 price target, signaling strong analyst conviction.
• Closely monitor Hikma's future financial reports for clarity on the projected 10.45% revenue decline and its impact on the $2.12 non-GAAP EPS, as these fundamentals could influence long-term valuation.
• Analyze the mixed institutional activity, weighing the substantial increase in total institutional shares and average portfolio weight against the reduction in positions by several large Vanguard funds.